Activation of heme biosynthesis by a small molecule that is toxic to fermenting Staphylococcus aureus by Mike, L. A. et al.
Activation of heme biosynthesis by a small molecule
that is toxic to fermenting Staphylococcus aureus
Laura A. Mikea, Brendan F. Dutterb, Devin L. Stauffa, Jessica L. Moorec,d, Nicholas P. Vitkoe, Olusegun Aranmolatea,
Thomas E. Kehl-Fiea, Sarah Sullivanf, Paul R. Reidb, Jennifer L. DuBoisg, Anthony R. Richardsone,
Richard M. Capriolic,d,h,i,j, Gary A. Sulikowskib,c, and Eric P. Skaara,b,1
aDepartment of Pathology, Microbiology and Immunology, Vanderbilt University School of Medicine, Nashville, TN 37232; bVanderbilt Institute for
Chemical Biology, Vanderbilt University Medical Center, Nashville, TN 37232; cDepartment of Chemistry, Vanderbilt University, Nashville, TN 37232;
dMass Spectrometry Research Center, Vanderbilt University, Nashville, TN 37232; eDepartment of Microbiology and Immunology, University of North Carolina,
Chapel Hill, NC 27599; fDepartment of Chemistry and Biochemistry, University of Notre Dame, Notre Dame, IN 46556; gBiosciences Division, SRI International,
Harrisonburg, VA 22802; and Departments of hBiochemistry, iPharmacology, and jMedicine, Vanderbilt University School of Medicine, Nashville, TN 37232
Edited by Scott J. Hultgren, Washington University School of Medicine, St. Louis, MO, and approved April 5, 2013 (received for review February 27, 2013)
Staphylococcus aureus is a significant infectious threat to global
public health. Acquisition or synthesis of heme is required for
S. aureus to capture energy through respiration, but an excess of
this critical cofactor is toxic to bacteria. S. aureus employs the heme
sensor system (HssRS) to overcome heme toxicity; however, the
mechanism of heme sensing is not defined. Here, we describe the
identification of a small molecule activator of HssRS that induces
endogenous heme biosynthesis by perturbing central metabolism.
This molecule is toxic to fermenting S. aureus, including clinically
relevant small colony variants. The utility of targeting fermenting
bacteria is exemplified by the fact that this compound prevents the
emergence of antibiotic resistance, enhances phagocyte killing, and
reduces S. aureus pathogenesis. Not only is this small molecule
a powerful tool for studying bacterial heme biosynthesis and cen-
tral metabolism; it also establishes targeting of fermentation as
a viable antibacterial strategy.
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The high incidence of hospital- and community-acquired infec-tions caused by methicillin-resistant Staphylococcus aureus
(MRSA) underscores the importance of identifying novel targets
for the treatment of this microbial threat (1). Upon breaching the
epithelium of its host, S. aureus has the potential to infect virtually
any tissue. This adaptability reflects the ability of S. aureus to
sense a variety of environmental signals and integrate them into
its metabolic program, enabling growth in diverse host niches.
To cause disease, S. aureus requires nutrient iron as a co-
factor for proteins involved in replication, metabolism, and
protection against reactive oxygen species (2). Within vertebrates,
the majority of iron is sequestered from invading pathogens as
heme bound to hemoglobin. S. aureus captures hemoglobin and
transports heme into the cell (3). S. aureus also synthesizes heme
endogenously through the coordinated effort of enzymes encoded
by the hemAXCDBL, hemEHY, and hemN operons (4). The ability
to exogenously acquire and endogenously synthesize heme allows
S. aureus to satisfy cellular iron and heme requirements in diverse
environments. This strategy is typical for most bacterial pathogens
and reflects the integral role of heme in metabolism and physiol-
ogy; however, the distinct contributions of endogenous and exog-
enous heme to the cellular physiology of bacteria are unknown.
Heme is a cofactor required for respiration. Furthermore,
S. aureus respiration requires that the bacteria either synthesize or
assimilate the electron carrier menaquinone (MK) and that a ter-
minal electron acceptor be available. During respiration, reducing
equivalents derived from the oxidation of carbon sources are do-
nated to MK. The shuttling of electrons by MK through the elec-
tron transport chain generates a proton motive force (pmf) across
the cytoplasmic membrane. The energy stored in the pmf powers
ATP synthesis and nutrient import. When heme, MK, or ter-
minal electron acceptors are absent, S. aureus generates energy
through fermentation. Fermentation employs substrate-level
phosphorylation, which produces acid end products, to generate
ATP and maintain the redox balance of the cell.
Small colony variants (SCVs) of S. aureus are spontaneous, slow-
growing mutants associated with persistent and recurrent S. aureus
infections that are recalcitrant to antibiotic therapy (5). Their slow
growth is often due to lesions that eliminate respiration, such as
inactivation ofMKor heme biosynthesis. SCVs are not exclusive to
S. aureus as they have been isolated in other pathogens, including
Escherichia coli, Neisseria gonorrhoeae, Pseudomonas aeruginosa,
and Salmonella enterica serovar Typhimurium (5, 6).
Without heme, many central metabolic pathways and enzymes
cannot function; however, excess heme is toxic due to its reactive
nature. Prior exposure of S. aureus to subinhibitory concen-
trations of heme increases heme tolerance (7). This adaptation is
due to the increased expression of the heme regulated transporter
HrtAB, an efflux pump that protects the bacteria from heme
toxicity. The increased expression of hrtAB is mediated by the
heme sensor system (Hss) two-component system (TCS). Com-
prised of the HssS-sensor kinase and HssR-response regulator,
HssRS is activated when the bacteria are exposed to heme
through an as-yet-unidentified mechanism (7). Functional hss/
hrt systems have been described in members of the genera
Staphylococcus, Bacillus, Listeria, Enterococcus, and Streptococ-
cus, establishing HssRS as a conserved heme responsive system
in Gram-positive bacteria (7, 8).
In this study, we probed the mechanism of HssS stimulation by
identifying smallmolecule activators of HssS. Themost potent com-
pound, VU0038882 (‘882), activatesHssRS by inducing endogenous
heme biosynthesis in S. aureus, leading to increased intracellular
heme levels. The metabolic alterations induced by ‘882 are toxic to
fermenting S. aureus. Therapeutic development of ‘882 has revealed
that this compound is synergistic with known respiration inhibitors,
is highly antimicrobial against fermenting bacteria including SCVs,
and virtually eliminates the development of resistance to amino-
glycoside antibiotics. Notably, a derivative of ‘882 reduces bacterial
burdens in a systemic model of staphylococcal infection, under-
scoring the therapeutic value of targeting bacterial fermentation.
Results
High-Throughput Screen Identifies Activators of HssRS. To perform
a high-throughput screen (HTS) for small molecule activators of
S. aureus HssRS, we created an hrtAB-driven expression system
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in the pXen-1 vector, which contains the Photorhabdus lumi-
nescens luciferase operon (luxABCDE) that produces blue-green
light when expressed (Fig. S1A). This construct was used to
screen a library of ∼160,000 small molecules and resulted in the
identification of 250 positive hits. Based on luminescence values,
the top 110 hits were subjected to a secondary screen using an
xylE reporter assay to eliminate compounds that generated non-
specific luminescence (7). Hits that passed this secondary screen
were further tested in a tertiary screen for their ability to adapt
S. aureus to heme toxicity by growth curve analyses (7). Of all of
the compounds screened, ‘882 was the most potent activator of
hrtAB expression. ‘882 activates the hrtAB promoter in a dose-
responsive manner requiring HssRS and preadapts S. aureus for
heme toxicity (Fig. 1). These properties were observed for both
commercially purchased and independently synthesized prep-
arations of ‘882 (Fig. S2). These results establish ‘882 as a small
molecule activator of the HssRS-dependent heme stress response.
‘882 Stimulates Heme Biosynthesis to Activate HssRS. To determine
the mechanism by which ‘882 activates HssRS, the residues re-
quired for HssS heme sensing were identified. An alignment of
the HssS extracytoplasmic domain frommembers of the Firmicutes
encoding putative hss/hrt systems was used to predict residues
required for heme sensing in S. aureus. Alanine substitution
mutants were generated at 10 highly conserved residues and 1
nonconserved residue (Fig. S3A). These HssS variants were
expressed in S. aureus ΔhssS, and their expression levels were
compared with wild type by immunoblot (Fig. S3B). Next, their
responsiveness to heme was quantified by XylE activity and growth
curve analyses (Fig. S3 C–E). Analogous to Bacillus anthracis
HssS, residues T125, F128, and R163 are required for heme
sensing and HssS function in S. aureus (9). To gain insight into
the mechanism by which ‘882 activates HssS, the ability of ‘882 to
activate HssS substitution mutants with heme sensing defects was
probed. R94A, T125A, and F165A were chosen for this analysis
as they represent three mutations that reduce HssS heme sensing
to different degrees. The impact of these mutations on HssS ac-
tivation by ‘882 mirrored that observed upon heme exposure (Fig.
S3F). This result indicates that heme and ‘882 trigger HssS sig-
naling through similar residues despite being structurally distinct.
This observation suggests that ‘882 triggers HssRS through
a mechanism similar to that of heme. A potential explanation
is that ‘882 is a small molecule activator of endogenous heme
synthesis. To test this model, the hrtAB promoter-xylE fusion re-
porter plasmid (phrt.xylE) was transformed into the heme auxo-
troph hemB::ermC (ΔhemB), and HssRS activation was evaluated
upon ‘882 exposure (10). In contrast to wild-type S. aureus, ‘882
does not activate HssRS in ΔhemB (Fig. 2A). The loss of ‘882-
mediated activation of HssRS in ΔhemB is not due to the slower
growth rate of this strain as XylE activity from a constitutively
expressed xylE (plgt.xylE) is only modestly decreased (Fig. 2A).
Furthermore, exogenous heme activates HssRS in ΔhemB, in-
dicating that ΔhemB HssRS is still able to sense heme (Fig. S1B).
These observations are consistent with a model whereby ‘882 ex-
posure leads to an increase in intracellular heme and subsequent
HssS activation. In support of this model, intracellular heme levels
increase in a dose-responsive manner in bacteria treated with ‘882
(Fig. 2 B and C). Moreover, ‘882 exposure leads to a darkening of
S. aureus pellets indicative of massive heme accumulation in these
cells (Fig. 2B, Inset). The activation of HssS by ‘882 is not due to
enzymatic degradation of heme as ‘882 still activates HssS in
a strain of S. aureus lacking all heme oxygenases (Fig. S1C) (11).
To determine whether the endogenous heme produced as
a result of ‘882 exposure is available for use in cellular processes,
cytoplasmic heme availability was measured by quantifying in-
tracellular levels of the cytoplasmic iron-regulated surface de-
terminate system heme oxygenase, IsdG. In the absence of
exogenous heme, IsdG is rapidly degraded; however, heme
binding stabilizes IsdG and reduces its proteolytic degradation
(11). Therefore, the abundance of IsdG reflects the cytoplasmic
levels of heme. Following ‘882 treatment, the intracellular abun-
dance of IsdG increased in a dose-dependent manner (Fig. S1 D
and E). IsdG is not stabilized when S. aureus ΔhemB is grown in the
presence of ‘882, demonstrating that stabilization of IsdG
requires endogenous heme (Fig. S1 D and E). Moreover, IsdG
abundance increases in ΔhemB exposed to exogenous heme, in-
dicating that heme-dependent stabilization of IsdG is not gen-
erally disrupted in this strain (Fig. S1 D and E). Taken together,
these experiments reveal that ‘882 exposure increases cytoplasmic
heme availability.
To test whether other bacterial heme sensing proteins monitor
endogenous heme, the ability of the Corynebacterium diphtheriae
ChrAS and Staphylococcus haemolyticus HssRS TCSs to sense
‘882 by adaptation growth curve was examined (7, 12, 13). Due to
the slow growth and low optical density achieved by C. diphtheriae,
enumerating colony forming units (cfus), a more sensitive measure
of growth, was used to assess the adaptation of this pathogen.
Pretreatment of both species with either heme or ‘882 improved
survival in heme compared with nonadapted cultures (Fig. 2 D
and E). These data suggest that ‘882 may stimulate heme bio-
synthesis in multiple Gram-positive bacteria and support the
hypothesis that the ability to respond to both endogenous and
exogenous heme is a conserved function of bacterial heme
sensor systems.
Fig. 1. A high-throughput screen identifies small molecule activators of
HssRS. (A) A secondary screen consisting of an XylE reporter assay verified
the activity of the top 110 hits from the primary screen, including ‘882.
Triplicate cultures of S. aureus WT and ΔhssR transformed with the hrtAB
promoter-xylE fusion-containing plasmid (phrt.xylE) were grown in the
presence of the indicated additive, and XylE activity was measured. (B) The
structure of lead compound VU0038882 (‘882). (C) ‘882 was confirmed as
the top hit in a tertiary screen that measured the ability of the compound to
preadapt S. aureus for growth in 20 μM heme. Triplicate cultures of WT
S. aureus were grown overnight in medium containing the indicated addi-
tive and subcultured into medium containing 20 μM heme. Growth was
monitored by measuring the optical density at 600 nm (OD600) over time. (A
and C) Error bars represent one SD from the mean.









‘882 Diminishes Fermentative Activity of S. aureus. To define the
mechanism by which ‘882 manipulates heme biosynthesis, an
S. aureus transposon library was screened for mutants unable
to sense ‘882 or heme by growth curve adaptation (7, 14). Of
the ∼7,000 mutants screened, only one strain was completely
unable to be preadapted for heme toxicity by ‘882; this strain
contained a transposon in the glutamate-1-semialdehyde ami-
notransferase (hemL) gene involved in heme biosynthesis.
Forty-four additional mutants were found to have a defect in
‘882 sensing, and, of those, 17 were also deficient in heme
sensing (Table S1). A number of genes required for sensing heme
and/or ‘882 are involved in central metabolic pathways including
a predicted α-D-1,4-glucosidase (malA), the catabolite control
protein (ccpA), respiratory response two-component system
(srrAB), branched-chain amino acid amino transferase (ilvE),
bifunctional pyrimidine regulator/uracil phosphoribosyltransfer-
ase (pryR), and pyridoxal 5′-phosphate synthase glutamine ami-
dotransferase subunit (pdxT) (2, 15, 16). Consistent with these
observations, bacteria treated with ‘882 had reduced glycolytic
activity as indicated by slower acidification of the medium that
correlated with delayed consumption of D-glucose and reduced
production of L- and D-lactate (Fig. 3). These observations suggest
that, as ‘882 induces endogenous heme biosynthesis, it also reduces
the glycolytic or fermentative capacity of S. aureus. These results
support a model whereby the metabolic state of S. aureus and
heme homeostasis are functionally interconnected.
To test whether heme biosynthesis interfaces with central me-
tabolism, we first assessed the effect of 2-deoxyglucose (2dG) on
heme biosynthesis. The glucose analog 2dG primarily inhibits the
phosphoglucoisomerase reaction, the second step in glycolysis
(17). Treatment of S. aureus with 2dG reduces endogenous
heme levels and antagonizes ‘882 activity (Fig. 4A). Deletion of
6-phosphofructokinase (pfkA), the third enzyme in glycolysis,
results in a loss of glucose uptake and decreased acid end product
secretion in S. aureus (Fig. S4 A and B). In agreement with the
effect of 2dG on heme biosynthesis, both basal and ‘882-induced
heme biosynthesis are suppressed in ΔpfkA (Fig. 4B). These data
implicate a product of glycolysis in stimulating heme biosynthesis,
strengthening the observed link between the regulation of heme
biosynthesis and central metabolism.
‘882 Is Bacteriostatic to Fermenting S. aureus. The ‘882-dependent
suppression of fermentative activity in aerobic cultures sug-
gests that the compound may inhibit fermentative growth.
Indeed, when S. aureus was grown anaerobically in the pres-
ence of ‘882, growth was dramatically reduced (Fig. 5A). In
Fig. 2. ‘882 acts through endogenous heme bio-
synthesis to activate HssRS and stimulate heme
production. (A) S. aureus wild type (WT, black lines)
and the heme auxotroph hemB::ermC (ΔhemB, gray
lines) were transformed with plasmids constitutively
expressing XylE (plgt.xylE, dashed lines) or with xylE
under the control of the hrtAB promoter (phrt.xylE,
solid lines). Triplicate cultures of these strains were
grown in the presence of ‘882, and XylE activity was
measured. (B) Heme levels in triplicate cultures of
S. aureus treated with the indicated additive were
quantified using the pyridine hemochromogen as-
say and normalized to the concentration of protein
in the whole cell lysates. (Inset) Pellets from a cul-
ture grown with 40 μM ‘882 are darker compared
with vehicle-treated S. aureus. (A and B) Error bars
represent 1 SD from the mean. (C) Exact-mass mass
spectrometric analysis was used in conjunction with
ultra-high performance liquid chromatography
(UPLC) to detect and quantify heme in protoplasts
from cells treated with 40 μM ‘882 or vehicle grown
in triplicate. Measured heme molecules were refer-
enced to estimated cfus per pellet, factoring in
dilutions. Dead or lysed cells would also contribute
to the measurement. Therefore the measured num-
bers are considered upper estimates. Samples mea-
sured in duplicate or triplicate injections had typical
errors of <5% between analytical replicates. Error
bars represent the SD, and significance was calcu-
lated using a two-tailed Student’s t test. (D) Adaptation by heme and ‘882 in C. diphtheriae was tested by growth analyses. Triplicate cultures were grown
overnight in medium containing vehicle, 5 μM heme or 50 μM ‘882 and subcultured into medium containing 15 μM heme. The cfus were enumerated 2.5 h after
inoculation and normalized to cultures unexposed to heme. Shown is the average of five replicates; error bars represent SEM and significance was determined
by a two-tailed Student’s t test. (E) Adaptation by heme and ‘882 in S. haemolyticus was tested by growth analyses. Triplicate cultures were grown overnight
in medium containing the indicated additive and subcultured into medium containing 30 μM heme. Growth was monitored by measuring the optical density at
600 nm (OD600) over time. Error bars represent 1 SD from the mean.
Fig. 3. ‘882 diminishes fermentative activity.
S. aureus was grown in triplicate under aerobic
conditions in the presence of vehicle (black lines)
or 40 μM ‘882 (gray lines). At the indicated time
intervals, culture supernatants were sampled and the
(A) pH, (B) D-glucose, and (C) D- and L-lactate were
quantified. Error bars represent 1 SD from the mean.
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addition, a strain bearing a lesion in the MK biosynthesis gene
menB (ΔmenB), which cannot respire and solely ferments to pro-
duce energy, is more susceptible to ‘882 toxicity than wild type
(Fig. 5A). ‘882 is bacteriostatic to ΔmenB both aerobically and
anaerobically (Fig. S4C). Moreover, when ‘882 is combined with
the respiratory poison potassium cyanide (KCN), S. aureus growth
is inhibited, even under aerobic conditions (Fig. S4D). Taken to-
gether, these data indicate that ‘882 inhibits S. aureus fermentative
growth and that respiration is protective against ‘882 toxicity.
Notably, ‘882 inhibits the growth of C. diphtheriae, supporting
the conserved activity of ‘882 in heme sensing organisms (Fig.
S4E). Furthermore, ΔhemB, an SCV deficient in heme bio-
synthesis, is also sensitive to ‘882, indicating that heme accu-
mulation is not the source of toxicity, but rather a result of ‘882
perturbing S. aureus metabolism (Fig. 5A).
‘882 Prevents the Evolution of Antibiotic Resistance. S. aureus SCVs
are obligate fermenters that emerge in response to aminoglycoside
treatment (5). Because ‘882 is toxic to fermenting staphylococci,
we hypothesized that ‘882 would prevent the outgrowth of an-
tibiotic resistant SCVs in the presence of aminoglycosides. To
test this hypothesis, S. aureus was grown in the presence of vehicle,
gentamicin, ‘882, or a combination of gentamicin and ‘882, and the
evolution of gentamicin resistance was monitored. Bacteria
treated with gentamicin alone became resistant to gentamicin
whereas ‘882 treatment alone did not affect the number of viable
or gentamicin-resistant bacteria (Fig. 5B). Combining ‘882 with
gentamicin resulted in a 5-log reduction in bacterial viability and
eliminated all detectable gentamicin-resistant colonies (Fig. 5B).
This improvement in gentamicin activity suggests that targeting
fermentation can be used as an adjunctive therapy with antibiotics
that are active against respiring S. aureus to improve antibacterial
action and reduce the emergence of antibiotic resistance.
‘882 Enhances Innate Immune Function. Neutrophils are the first
immune cells to respond to the site of a S. aureus infection (18). As
part of the innate defense program, they secrete noxious chemicals
to kill invading pathogens (18). One component of this toxic milieu
is nitric oxide (NO·), which inactivates iron-containing proteins
critical for respiration (19). In agreement with the observation that
‘882 is particularly toxic to fermenting S. aureus, simultaneous
exposure of S. aureus to ‘882 and NO· is more antibacterial than
treatment with eithermolecule alone (Fig. S4F). Additionally, ‘882
improves neutrophil-dependent killing of S. aureus but does not
overtly affect neutrophil viability (Fig. 5C). These results support
the notion that ‘882may have therapeutic efficacy against bacterial
invaders by augmenting the killing activity of neutrophils.
Derivative of ‘882 Reduces S. aureus Pathogenesis in Vivo.Abscesses,
which are purulent lesions containing bacteria and neutrophils
surrounded by a pseudocapsule, are a hallmark of S. aureus infec-
tions (20). It is likely that fermentation is critical to staphylococcal
pathogenesis because abscesses are thought to be anaerobic envi-
ronments (21). Testing this hypothesis is challenging as S. aureus
fermentation is branched, so genetic inactivation of fermentation is
difficult. The toxic effect of ‘882 toward fermenting S. aureus pro-
vides an opportunity to gain initial insights into the role of fer-
mentation in pathogenesis. However, ‘882 has ametabolically labile
Fig. 4. Glycolytic activity regulates heme biosynthesis. S. aureus was
grown in triplicate in the presence of vehicle or 10 μM ‘882. Heme levels
were quantified using the pyridine hemochromogen assay and normal-
ized to the concentration of protein in the whole cell lysates. (A) Cultures
were treated with the indicated dose of 2-deoxyglucose (2dG). *P ≤ 0.05,
**P ≤ 0.001, ***P ≤ 0.0001. (B) Wild-type (WT) and ΔpfkA Newman were
cultured in TSB + 1% pyruvate. #, the signal was below the limit of de-
tection. (A and B) Error bars represent the SEM from three independent
experiments. Statistical significance was determined using an unpaired
Student’s t test.
Fig. 5. ‘882 inhibits fermenting S. aureus. (A) S. aureus wild type (WT, dashed lines), the menaquinone auxotroph (ΔmenB, dotted lines), and the heme
auxotroph hemB::ermC (ΔhemB, solid lines) were grown in triplicate under aerobic (aer, black lines) and anaerobic (ana, gray lines) conditions in the presence of
the indicated log of the concentration of ‘882 (μM). After 18 h, the absorbance at 600 nm (OD600) was measured and normalized to vehicle (DMSO)-treated
bacteria. Curves were fit by nonlinear regression analysis and absolute logIC50 values were calculated in Prism with the top set at 1.0 and the bottom set at 0.15.
LogIC50 values are indicated in parentheses in the figure key ±SEM. All logIC50 values were statistically different fromWT aerobic logIC50 when analyzed by one-
way ANOVA with a Dunnett post test (P < 0.001). Error bars represent the SEM. (B) Triplicate cultures of S. aureus were grown in the presence of the indicated
additive. After 24 h, cfus were enumerated on tryptic soy agar (TSA) containing 5 μg/mL gentamicin (Gent) and plain TSA with a limit of detection of 100 cfus/mL
(minimum y value); #, colonies were not identified above the limit of detection. Shown is the average of three independent experiments. Error bars represent 1 SD
from the mean. (C) S. aureus was grown in the presence of vehicle (DMSO) or 40 μM ‘882 and coated in serum. Murine polymorphonuclear leukocytes (PMNs)
were elicited with casein and harvested from the peritoneum. The ability of neutrophils to kill S. aureus in the presence of ‘882 was assessed by comparing cfus
recovered from neutrophil-exposed S. aureus with those recovered from identical conditions lacking neutrophils. The mean of at least six independent experi-
ments performed in triplicate are represented by the data; error bars represent SEM and significance was determined by a two-tailed Student’s t test.









furan group that may form protein adducts and deplete glutathione
in vivo (22). Thus, the furan was replaced with a 2-fluorophenyl
group to create a more biologically stable derivative, VU0420373
(‘373) (Figs. S5 and S6A). ‘373 activates HssRS as evidenced by its
ability to increase the expression of the xylE reporter gene and
preadapt S. aureus for heme toxicity (Fig. S6 B and C). In addition,
‘373 inhibits the growth of S. aureus ΔmenB, although to a lesser
extent than ‘882 (Fig. S6D).
Intraperitoneal administration of ‘373 to mice i.v. infected with
S. aureus resulted in a significant 1-log decrease in cfus recovered
from the livers of ‘373-treated animals compared with vehicle (Fig.
6A). Notably, ‘373 treatment reduced tissue pathology associated
with infection as demonstrated by a significant reduction in the
number of liver abscesses (Fig. 6B). This liver-specific reduction in
bacterial burden and inflammation correlateswith an accumulation
of ‘373 in the livers of treated animals as shown by Imaging Mass
Spectrometry (IMS) (Fig. 6C,D and Fig. S7A–C) (23). To quantify
the tissue level of ‘373, portions of the livers were excised, and ’373
concentrations were determined by HPLC-MS (Fig. S7D). A
linear relationship between tissue level and dose of ‘373 admin-
istered was observed. Average spectral intensity extrapolated
from IMS data of ’373 reflected a dose–response relationship
similar to that observed byHPLC-MS, confirming the suitability of
IMS for monitoring tissue levels of ’373 (Fig. S7E). Both the
HPLC-MS and IMS data support the notion that the therapeutic
effect of ‘373 is due to the interaction of the compound with
S. aureus as it is found at the site where bacterial growth is restricted.
Although the therapeutic benefits of ‘373 could be due to alterna-
tive activities of this molecule, these results provide evidence that
targeting fermentation in a facultative anaerobe may be a viable
therapeutic strategy. The therapeutic value of this strategy is sup-
ported by the observation that S. aureus generates resistance to ‘882
in anaerobic conditions with a frequency of ∼1 in 10−7 cfus.
Discussion
Here, we describe anHTS that identified small molecule activators
of the S. aureus heme sensor system HssRS. The most potent hit,
‘882, increases endogenous heme levels and activates HssRS
through the heme biosynthesis pathway. This effect appears to be
due to a perturbation of the metabolic state of S. aureus as trans-
poson insertions targeting genes involved inmetabolism contribute
to the ability of the bacteria to sense ‘882. This hypothesis is sup-
ported by the observations that ‘882 reduces fermentative pro-
cesses and is bacteriostatic to fermenting staphylococci. Targeting
staphylococcal fermentation has therapeutic potential as it aug-
ments innate immune function and prevents outgrowth of antibi-
otic resistant colonies in vitro, and reduces S. aureus liver
colonization and associated inflammation in vivo.
Using ‘882 as a probe has revealed that HssRS responds to both
exogenous and endogenous heme accumulation. The discovery
that S. aureus monitors intracellular heme status through HssRS
suggests that other bacterial heme sensing systems may also sense
intracellular heme. This hypothesis is supported by the observa-
tion that C. diphtheriae and S. haemolyticus are also adapted for
heme toxicity by ‘882 (12). The fact that ‘882 is sensed by C.
diphtheriae and S. haemolyticus indicates that the target of ‘882 is
present in multiple pathogens, establishing this molecule as
a powerful probe for studying intracellular heme metabolism. The
utility of ‘882 as a probe is further supported by the observation
that IsdG binds endogenously synthesized heme following stimu-
lation with ‘882. This result implicates bacterial heme oxygenases
in intracellular heme turnover, a result that is likely generalizable
to all bacterial heme oxygenases as P. aeruginosa HemO has also
been shown to act on endogenous heme (24). Expanding the
function of bacterial heme degrading enzymes beyond nutrient
iron acquisition establishes a mechanism by which bacteria can
adjust iron and heme levels to satisfy cellular needs (3, 11).
Heme biosynthesis is typically regulated by cellular iron or
heme levels although there is some evidence that it is tied to
central metabolism (25, 26). The perturbation of heme homeo-
stasis and central metabolism by ‘882 suggests that the two cel-
lular processes are coordinated in S. aureus. Strengthening this
hypothesis, both chemical and genetic inhibition of the upper
steps in glycolysis result in suppressed basal and ‘882-induced
heme levels. These data suggest that an intact glycolytic pathway
is required for ‘882-dependent activation of heme biosynthesis,
further supporting a functional interconnection between central
metabolism and heme biosynthesis in S. aureus. An integration of
heme homeostasis with central metabolism is consistent with the
fact that heme and iron are critical cofactors for many enzymes
involved in energy conversion. Further studies using ‘882 could
dissect the interplay between heme and central metabolism in
both S. aureus and other pathogens.
The activity of ‘882 against fermenting bacteria has broad
therapeutic potential. ‘882 is bacteriostatic to SCVs, which often
emerge during recurrent and persistent S. aureus infections (5).
This therapeutic strategy may be generalizable across other in-
fectious diseases because N. gonorrhoeae, E. coli, P. aeruginosa,
and S. Typhimurium can also spawn SCVs (5, 6). In addition to
being used as a treatment for persistent infections, derivatives of
‘882 could have utility in combinatorial therapy with antibiotics
that target respiring bacteria. As a proof of principle, cotreating S.
Fig. 6. ‘373 reduces S. aureus pathogenesis in vivo. Mice infected retro-
orbitally with S. aureus were treated intraperitoneally with vehicle [10%
(vol/vol) Tween 80] or ‘373. After 96 h, mice were euthanized and (A) cfus
and (B) surface abscesses were enumerated from the livers. Each marker
represents an individual mouse. Data were collected from three in-
dependent experiments resulting in n = 13 for vehicle and n = 12 for ‘373-
treated mice once the highest and lowest values were removed from each
group. The horizontal line indicates the mean and the error bars represent
the SEM. Statistical significance was determined by a two-tailed Student’s t
test. Livers from mice treated with the indicated dose of ‘373 were harvested
24 h postinfection (1 h after the second treatment), sectioned, and mounted
on MALDI target plates (C). (D) Tissue sections were imaged by MALDI-MS/
MS for accumulation of a fragment of ‘373 by MALDI-MS/MS (m/z
255.2→134). Spectra were acquired at 10 microscans per step. Five laser shots
were acquired per pixel, and pixels were obtained every 100 μm.
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aureus with gentamicin and ‘882 in vitro reduces bacterial viability
and the outgrowth of antibiotic resistant populations. Although
gentamicin is typically used in combination with other primary
antibiotic agents, it is often conjugated to beads and used as the
primary antibiotic agent at the site of osteomyelitis infections.
SCVs often arise during the prolonged antibiotic regimen required
for treatment of osteomyelitis. Therefore, it is possible that an
‘882–gentamicin dual therapy could be used to improve therapy
for osteomyelitis by preventing the generation of SCVs during
infection. If ‘882 proves synergistic with other primary anti-
staphylococcal agents such as β-lactams and vancomycin, it is
possible that ‘882 could be used more broadly as an adjuvant to
expand the antibiotic armamentarium that is effective against
S. aureus infections.
The majority of bacterial pathogens use some combination of
fermentation and respiration to produce ATP, suggesting that both
are important for colonization and persistence (27). The impor-
tance of S. aureus fermentative pathways during infection is dem-
onstrated by the fact that ‘373 reduces abscess formation and
S. aureus growth in the livers of systemically infected mice. The
observed effects of ‘373 on S. aureus pathogenesis support the no-
tion that the abscess is an anaerobic environment and that bacterial
fermentation is required for efficient colonization (21). Further-
more, the modest effect ‘373 has on S. aureus pathogenesis in
vivo, despite its diminished bacteriostatic activity in vitro,
highlights the promise of more potent, biologically compatible
derivatives of ‘882 as novel therapeutics.
In summary, we have identified a small molecule that dimin-
ishes fermentative processes in S. aureus, stimulates endogenous
heme biosynthesis, and activates the HssRS heme sensor. This
molecule has twofold utility as both a probe of bacterial physiology
and an unconventional therapeutic. Tools for stimulating endog-
enous heme biosynthesis are limited, and these probes, which
stimulate heme biosynthesis across genera, will provide insight
into conserved mechanisms of heme regulation. As a therapeutic,
further studies confirming the mechanisms by which ‘882-derived
compounds reduce S. aureus pathogenesis and associated in-
flammation in vivo will lay the groundwork for improved strategies
for treating recalcitrant infections.
Materials and Methods
Descriptions of the bacterial strains and growth conditions, high-throughput
screen, XylE reporter assay, growth curve analyses, metabolite detection,
heme quantification, transposon site identification, gentamicin resistance
assay, neutrophil killing assay, murine infection, IMS and HPLC-MS analysis of
‘373, small molecule synthesis, and statistical analyses are in the SI Materials
and Methods. Primers used for generating ΔpfkA and identifying trans-
poson integration sites are listed in Table S2. All animal experiments were
reviewed and approved by Vanderbilt University’s Institutional Animal Care
and Use Committee.
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